{"id":206953,"name":"BOEHRINGER INGELHEIM","slug":"boehringer-ingelheim","state":"DC","description":"pharmaceutical company focused on innovative therapies for diseases w/o treatment option","totalSpending":1540000,"filings":21,"yearlySpending":[{"year":2020,"income":80000},{"year":2021,"income":360000},{"year":2022,"income":390000},{"year":2023,"income":290000},{"year":2024,"income":280000},{"year":2025,"income":140000}],"firms":["TARPLIN, DOWNS & YOUNG, LLC"],"lobbyists":["RAISSA DOWNS","JENNIFER YOUNG","MICHELLE EASTON","ELIZABETH MURRAY","CHARLOTTE IVANCIC","PAMELA SMITH","EMILY MURRY","KIMBERLY BRANDT","MARGARET JOSEPH","PETER FISE","LAURA FRIEDEL","PARICK CARROLL"],"issues":["HCR","MMM","BUD",null],"sampleDescriptions":["Prescription drug access and affordability, FDA user fee reauthorization","Medicaid value based payment proposed rule \ncovid therapeutics, pandemic response, Medicare drug cards, most favored nation policy\nH.R. 133 - Consolidated Appropriations Act, 2021","government funding\nH.R. 8337 - Continuing Appropriations Act of 2021\nH.R. 133 - Consolidated Appropriations Act, 2021","Medicaid value based payment proposed rule\ncovid therapeutics, pandemic response, Medicare drug cards, most favored nation policy\nH.R. 1319, American Rescue Pan of 2021","government funding, deficit reduction\nS. Con. Res. 5 (117)","prescription drug pricing\nH.R. 1319, American Rescue Plan of 2021","prescription drug pricing\nH.R. 1319, American Rescue Pan of 2021 implementation\nprescription drug access and affordability, pricing, transparency","Medicaid value based payment proposed rule\ncovid therapeutics, pandemic response, Medicare drug cards, most favored nation policy\nH.R. 1319, American Rescue Pan of 2021 implementation\nregulatory and payment issues","government funding, deficit reduction, reconciliation, FY2022 budget, appropriations\nS. Con. Res. 5 (117)","Medicaid value based payment proposed rule\ncovid therapeutics, pandemic response, Medicare drug cards, most favored nation policy\nH.R. 1319, American Rescue Plan of 2021 implementation\nregulatory and payment issues","prescription drug pricing\nH.R. 1319, American Rescue Plan of 2021 implementation\nprescription drug access and affordability, pricing, transparency","prescription drug pricing\nprescription drug access and affordability, pricing, transparency\nH.R. 1319, American Rescue Plan of 2021 implementation\nH.R. 3, The Lower Drug Costs Now Act","government funding, deficit reduction, reconciliation, FY2022 budget, appropriations\nS. Con. Res. 14","prescription drug pricing\nprescription drug access and affordability, pricing, transparency\nH.R. 1319, American Rescue Plan of 2021 implementation\nH.R. 5376, the Build Back Better Act","government funding, deficit reduction, reconciliation, FY2022 budget, appropriations H.R. 2471, Consolidated Appropriations Act 2022","covid therapeutics, pandemic response, regulatory and payment issues","prescription drug pricing, prescription drug access and affordability, pricing, transparency, user fees H.R. 5376, the Build Back Better Act","H.R. 2471, Consolidated Appropriations Act 2022 government funding, deficit reduction, reconciliation, FY2022 budget, appropriations","S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R. 5376, the Build Back Better Act prescription drug pricing, prescription drug access and affordability, pricing, transparency, user fees","H.R. 6833, Continuing Appropriations and Ukraine Supplemental Appropriations Act of 2023"],"years":[2020,2021,2022,2023,2024,2025]}